NCT03380130View on ClinicalTrials.gov

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

March 1, 2020

Study Completion Date

November 4, 2020

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Nivolumab

An anti-programmed death 1 monoclonal antibody

DEVICE

SIR-Spheres

Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation

Trial Locations (9)

31008

Clinica Universidad de Navarra, Pamplona

Unknown

Hospital Universitario de Cruces, Barakaldo

Hospital Clinic, Barcelona

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Gregorio Marañon, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario Central de Asturias, Oviedo

Hospital Universitario Donostia, San Sebastián

Hospital Universitario Lozano Blesa, Zaragoza

Sponsors
All Listed Sponsors
collaborator

Sirtex Medical

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER